Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique

Drug Development and Industrial Pharmacy

Volumn 41, Issue 9, 2015, Pages 1416-1424

  Ye, Yanghuan ^a   Zhang, Xingwang ^a   Zhang, Tianpeng ^a   Wang, Huan ^a   Wu, Baojian ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Antitumor activity; Intravenous delivery; Nanocrystals; Niclosamide; Pharmacokinetics; Tissue distribution

Indexed keywords

ANTINEOPLASTIC AGENT; NANOCRYSTAL; NICLOSAMIDE; POLYSORBATE 80; ANTHELMINTIC AGENT; NANOPARTICLE; POLYSORBATE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL LINE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG SOLUTION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ELECTRON MICROSCOPY; ESOPHAGUS CARCINOMA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; WET MEDIA MILLING TECHNIQUE; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; ESOPHAGEAL NEOPLASMS; HUMAN; MEDICINAL CHEMISTRY; PATHOLOGY; PROCEDURES; SOLUBILITY; SPRAGUE DAWLEY RAT; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ANTHELMINTICS; ANTINEOPLASTIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; ESOPHAGEAL NEOPLASMS; HUMANS; NANOPARTICLES; NICLOSAMIDE; PARTICLE SIZE; POLYSORBATES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84964253162     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.954585     Document Type: Article

References (33)

1. Zhang X, Wu W. Ligand-mediated active targeting for enhanced oral absorption. Drug Discov Today. 2014; 19: 898-904.
2. Williams HD, Trevaskis NL, Charman SA, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 2013; 65: 315-499.
3. Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: Biological rationale and pharmaceutical perspectives. Nanomedicine 2012; 7: 1577-90.
4. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Del Rev 2013; 65: 36-48.
5. Gupta S. Biocompatible microemulsion systems for drug encapsulation and delivery. Curr Sci 2011; 101: 174-88.
6. Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm 2013; 453: 198-214.
7. Qi J, Lu Y, Wu W. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. Curr Drug Metab 2012; 13: 418-28.
8. Xu S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF. Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances. Adv Drug Del Rev 2013; 65: 121-38.
9. Moschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm 2013; 453: 142-56.
10. Carter NJ. Extended-release intramuscular paliperidone palmitate: A review of its use in the treatment of schizophrenia. Drugs 2012; 72: 1137-60.
11. Sudhakar B, NagaJyothi K, Murthy KV. Nanosuspensions as a Versatile Carrier based Drug Delivery System - An Overview. Curr Drug Deliv 2014; 11: 299-305.
12. Ali HSM, York P, Blagden N. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm 2009; 375: 107-13.
13. Hollis CP, Weiss HL, Leggas M, et al. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: Lessons learned of the EPR effect and image-guided drug delivery. J Control Release 2013; 172: 12-21.
14. Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006; 62: 3-16.
15. Van Eerdenbrugh B, Van Den Mooter G, Augustijns P. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008; 364: 64-75.
16. Chen H, Wan J, Wang Y, et al. A facile nanoaggregation strategy for oral delivery of hydrophobic drugs by utilizing acid-base neutralization reactions. Nanotechnology 2008; 19: 375104.
17. Gao L, Liu GY, Wang XQ, et al. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Int J Pharm 2011; 404: 231-7.
18. Xia D, Gan Y, Cui F. Application of precipitation methods for the production of water-insoluble drug nanocrystals: Production techniques and stability of nanocrystals. Curr Pharm Des 2014; 20: 408-35.
19. Muller RH, Gohla S, Keck CM. State of the art of nanocrystals- special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011; 78: 1-9.
20. Li Y, Li PK, Roberts MJ, et al. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Lett 2014; 349: 8-14.
21. Tuomela A, Liu P, Puranen J, et al. Brinzolamide nanocrystal formulations for ophthalmic delivery: Reduction of elevated intraocular pressure in vivo. Int J Pharm 2014; 467: 34-41.
22. Liu H, Sun H, Lu D, et al. Identification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: In vivo and in vitro evidence. Xenobiotica 2014; 44: 696-707.
23. Jin Y, Chen Q, Shi X, et al. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci 2009; 100: 1335-43.
24. Honary S, Zahir F. Effect of zeta potential on the properties of nanodrug delivery systems - A review (part 2). Trop J Pharm Res 2013; 12: 265-73.
25. Van Eerdenbrugh B, Van Den Mooter G, Augustijns P. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008; 364: 64-75.
26. Guo Y, Luo J, Tan S, et al. The applications of Vitamin E TPGS in drug delivery. Eur J Pharm Sci 2013; 49: 175-86.
27. Deng J, Huang L, Liu F. Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm 2010; 390: 242-9.
28. Kenth S, Sylvestre JP, Fuhrmann K, et al.Fabrication of paclitaxel nanocrystals by femtosecond laser ablation and fragmentation. J Pharm Sci 2011; 100: 1022-30.
29. Li Y, Sun S, Chang Q, et al. A strategy for the improvement of the bioavailability and antiosteoporosis activity of BCS IV flavonoid glycosides through the formulation of their lipophilic aglycone into nanocrystals. Mol Pharm 2013; 10: 2534-42.
30. Liu Y, Huang L, Liu F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm 2010; 7: 863-9.
31. Zhang H, Hollis CP, Zhang Q, Li T. Preparation and antitumor study of camptothecin nanocrystals. Int J Pharm 2011; 415: 293-300.
32. Mouton JW, van Peer A, de Beule K, et al. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 2006; 50: 4096-102.
33. Bucke WE, Leitzke S, Diederichs JE, et al. Surface-modified amikacin-liposomes: Organ distribution and interaction with plasma proteins. J Drug Target 1998; 5: 99-108.